Insider Selling: Gyre Therapeutics (NASDAQ:GYRE) CEO Sells $81,493.44 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) CEO Ying Luo sold 10,136 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the sale, the chief executive officer owned 2,565,226 shares of the company’s stock, valued at approximately $20,624,417.04. This trade represents a 0.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ying Luo also recently made the following trade(s):

• On Tuesday, May 5th, Ying Luo sold 179 shares of Gyre Therapeutics stock. The shares were sold at an average price of $8.01, for a total transaction of $1,433.79.

Gyre Therapeutics Trading Up 5.7%

NASDAQ:GYRE opened at $7.47 on Friday. The firm has a market capitalization of $724.52 million, a price-to-earnings ratio of -82.99 and a beta of 2.03. Gyre Therapeutics, Inc. has a 1-year low of $6.57 and a 1-year high of $11.78. The business’s fifty day moving average price is $7.58 and its 200 day moving average price is $7.69.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $37.20 million for the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.14%. Equities analysts forecast that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Gyre Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.00.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue bought a new position in Gyre Therapeutics during the third quarter valued at approximately $38,000. Bank of America Corp DE raised its position in Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. raised its position in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after acquiring an additional 3,244 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Gyre Therapeutics during the fourth quarter valued at approximately $77,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.